Get started
Author

Stefania Zambelli

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
2021 · Eric P Winer, Oleg Lipatov, et al. · The Lancet Oncology · 505
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
2022 · L. Gianni, C.S. Huang, et al. · Annals of Oncology · 407
PDF
Spatial predictors of immunotherapy response in triple-negative breast cancer
2023 · Xiao Qian Wang, Esther Danenberg, et al. · Nature · 375
PDF
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
2020 · Sara M Tolaney, Andrew M Wardley, et al. · The Lancet Oncology · 260
Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
2020 · Luca Gianni, Chiun-Sheng Huang, et al. · Cancer Research · 135
KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
2019 · J. Cortés, O. Lipatov, et al. · Annals of Oncology · 131
Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)
2020 · Sherene Loi, Eric Winer, et al. · Cancer Research · 69
LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
2020 · G. Bianchini, C-S. Huang, et al. · Annals of Oncology · 53
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak
2020 · Giulia Viale, Luca Licata, et al. · The Oncologist · 35
PDF
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
2022 · Luca Gianni, Marco Colleoni, et al. · npj Breast Cancer · 30
PDF
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
2019 · S.M. Tolaney, A.M. Wardley, et al. · Annals of Oncology · 24
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice
2024 · Giulia Notini, Matteo Maria Naldini, et al. · Frontiers in Oncology · 19
PDF
Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial
2022 · Giampaolo Bianchini, Xiao Qian Wang, et al. · Cancer Research · 17
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
2019 · Véronique Diéras, Hervé Bonnefoi, et al. · Breast Cancer Research and Treatment · 17
Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study
2011 · Michele Magni, Massimo Di Nicola, et al. · Blood · 15
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
2023 · Peter Schmid, Oleg Lipatov, et al. · European Journal of Cancer · 14
PDF
Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL)
2008 · Carmelo Carlo-Stella, Anna Guidetti, et al. · Blood · 10
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
2025 · Maurizio Callari, Matteo Dugo, et al. · Nature Communications · 8
Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.
2019 · Luca Gianni, Marco Colleoni, et al. · Journal of Clinical Oncology · 7
Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases
2021 · Eric Winer, Oleg Lipatov, et al. · Cancer Research · 5
44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation
2020 · S-A. Im, J. Cortes, et al. · Annals of Oncology · 4
Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial.
2020 · Giampaolo Bianchini, Chanel Smart, et al. · Journal of Clinical Oncology · 4
De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice
2026 · Irene Persano, Luca Licata, et al. · Cancer Treatment Reviews · 3
PDF
Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial
2010 · Carmelo Carlo-Stella, Anna Guidetti, et al. · Blood · 3
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
2025 · Justin M. Balko, Luca Licata, et al. · npj Breast Cancer · 2
PDF
Works count: 73
Citation count: 2,163
H-index: 15
I10-index: 17
Year
Topic
Type